Changeflow GovPing Pharma & Drug Safety PRIMROSE BIO Patent: Single-Subunit RNA Polymer...
Routine Rule Added Final

PRIMROSE BIO Patent: Single-Subunit RNA Polymerase Polynucleotide Synthesis

Favicon for changeflow.com USPTO Patent Grants - Biotech (C12N)
Published
Detected
Email

Summary

USPTO granted Patent US12600958B2 to PRIMROSE BIO, INC. on April 14, 2026. The patent covers compositions and methods for polynucleotide synthesis in vitro using single-subunit RNA polymerases. The application (No. 17614286, filed May 23, 2020) contains 9 claims under CPC classifications including C12N 9/1247 and C12P 19/34.

What changed

USPTO issued Patent US12600958B2 to PRIMROSE BIO, INC. for methods and compositions in polynucleotide manufacturing via single-subunit RNA polymerases. The patent covers in vitro RNA synthesis technology developed by five inventors including Dongxin Karen Xu and Helge Zieler.

Affected parties in the biotech and pharmaceutical RNA synthesis space should conduct freedom-to-operate analyses to assess whether PRIMROSE BIO's patent claims may affect their research, development, or manufacturing activities. Competitors developing similar RNA polymerase-based synthesis methods may need to consider licensing or design-around strategies.

What to do next

  1. Monitor patent portfolio for potential licensing opportunities
  2. Review patent claims for freedom-to-operate analysis

Archived snapshot

Apr 16, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Methods and compositions for manufacturing polynucleotides

Grant US12600958B2 Kind: B2 Apr 14, 2026

Assignee

PRIMROSE BIO, INC.

Inventors

Dongxin Karen Xu, Kadir Chir Tung, Sabrina Baffert, Alan Greener, Helge Zieler

Abstract

The present disclosure provides compositions and methods for polynucleotide synthesis in vitro, specifically the use of single-subunit RNA polymerases for synthesis and manufacturing of RNA.

CPC Classifications

C12N 15/63 C12N 9/1247 C12P 19/34 C12Q 1/6865 C12Q 2525/143 C12Q 2531/143 C12Y 207/07006

Filing Date

2020-05-23

Application No.

17614286

Claims

9

View original document →

Named provisions

Methods and compositions for manufacturing polynucleotides

Get daily alerts for USPTO Patent Grants - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600958B2

Who this affects

Applies to
Pharmaceutical companies Manufacturers
Industry sector
3254.1 Biotechnology
Activity scope
Patent grant RNA synthesis technology Biotech manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Biotechnology

Get alerts for this source

We'll email you when USPTO Patent Grants - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!